Nancy Stagliano bags another $45M for True North’s rare disease R&D
Nancy Stagliano has a habit of remaining precisely on message when she talks about South San Francisco-based True North Therapeutics.
Her new $45 million round announced today brings the total she’s raised for the biotech to $142 million. Yes, she says she still has some of that earlier cash raised in the bank. But don’t look for her to tout how much runway she has now, what kind of development timelines are on the chalk board or say much about the prospect of an IPO after a round that includes investors like Franklin Templeton Investments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.